Stephen V Liu: Dr. Passiglia Fra at Rome Lung 24 illustrates the limited role of immunotherapy in driver positive NSCLC
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University at Lombardi Cancer shared on X:
“Dr. Passiglia Fra at Rome Lung 24 illustrates the limited role of immunotherapy in driver positive Non-Small Cell Lung Cancer and the toxicity seen when combining immunotherapy and Tyrosine Kinase Inhibitors. Exception is KRAS, where 1L immunotherapy is our standard and combinations may be safe – work ongoing here.”
Source: Stephen V Liu/X
Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
